Khan Jaffar, Ullah Asad, Goodbee Mya, Lee Kue Tylor, Yasinzai Abdul Qahar Khan, Lewis James S, Mesa Hector
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Department of Pathology, Microbiology, Immunology Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Cancers (Basel). 2023 Jun 27;15(13):3373. doi: 10.3390/cancers15133373.
Acinic cell carcinoma (AciCC) comprises 6-7% of all salivary gland neoplasms and is the second most common salivary gland malignancy in children. Like many salivary gland carcinomas, it is considered low grade but occasionally it behaves aggressively. Understanding the risk factors associated with recurrence, metastasis, and death is important to determine the counseling and management of individual patients. Older population-based studies are presumed to have been confounded by the misclassification of other neoplasms as AciCC, in particular secretory carcinoma and cystadenocarcinoma. Since diagnostic tools to reliably separate these entities have been available for over a decade, reevaluation of epidemiologic data limited to the 21st century should allow a better characterization of the clinicopathological characteristics of AciCC.
Our study extracted data from the Surveillance, Epidemiology, and End Results (SEER) database for the period 2000 to 2018. Cox regression model analysis was performed to identify risk factors independently affecting survival.
Data for 2226 patients with AciCC were extracted from the database. Most patients were females: 59%, and white: 80.5%, with a mean age at diagnosis of 51.2 (SD ± 18.7) years. Most cases (81%) were localized at presentation. Tumor size was less than 2 cm in 42%, 2-4 cm in 47%, and >4 cm in 11%. Low-grade tumors had 5-year survival > 90%, whereas high-grade tumors had survival < 50%. Of the patients with known lymph node status only 7.3% had nodal metastases. Distant metastases were documented in 1.1%, involving lungs 44%, bone 40%, liver 12%, and brain 4%. The most common treatment modality was surgery alone: 63.6% followed by surgery and adjuvant radiation: 33%. A few received chemotherapy (1.8%) or multimodality therapy (1.2%). The 5-year overall survival rate was 90.6% (95%CI 89.1-91.9), and disease-specific survival was 94.6% (95%CI 93.3-95.6). Multivariable cox regression analysis showed that undifferentiated (HR = 8.3) and poorly differentiated tumor grade (HR = 6.4), and metastasis (HR = 5.3) were the worst independent prognostic factors. Other poor risk factors included age > 50 (HR = 3.5) and tumor size > 4 cm (HR = 2.5).
In the US, AciCC is more common in middle age white females, and most tumors are less than 4 cm and localized at diagnosis. The most relevant negative prognostic factor was high tumor grade which was associated with higher hazard ratios for death than all other variables, including regional or distant metastases at presentation.
腺泡细胞癌(AciCC)占所有涎腺肿瘤的6%-7%,是儿童第二常见的涎腺恶性肿瘤。与许多涎腺癌一样,它被认为是低级别肿瘤,但偶尔也会表现出侵袭性。了解与复发、转移和死亡相关的风险因素对于确定个体患者的咨询和管理很重要。基于人群的早期研究可能因将其他肿瘤误诊为AciCC而产生混淆,特别是分泌性癌和囊腺癌。由于可靠区分这些实体的诊断工具已经出现了十多年,对21世纪的流行病学数据进行重新评估应该能够更好地描述AciCC的临床病理特征。
我们的研究从监测、流行病学和最终结果(SEER)数据库中提取了2000年至2018年期间的数据。进行Cox回归模型分析以确定独立影响生存的风险因素。
从数据库中提取了2226例AciCC患者的数据。大多数患者为女性:59%,白人:80.5%,诊断时的平均年龄为51.2(标准差±18.7)岁。大多数病例(81%)在就诊时为局限性病变。肿瘤大小小于2cm的占42%,2-4cm的占47%,大于4cm的占11%。低级别肿瘤的5年生存率>90%,而高级别肿瘤的生存率<50%。在已知淋巴结状态的患者中,只有7.3%有淋巴结转移。远处转移记录为1.1%,其中肺部转移占44%,骨转移占40%,肝转移占12%,脑转移占4%。最常见的治疗方式是单纯手术:63.6%,其次是手术加辅助放疗:33%。少数患者接受化疗(1.8%)或多模式治疗(1.2%)。5年总生存率为90.6%(95%CI 89.1-91.9),疾病特异性生存率为94.6%(95%CI 93.3-95.6)。多变量Cox回归分析显示,未分化(HR = 8.3)和低分化肿瘤分级(HR = 6.4)以及转移(HR = 5.3)是最不利的独立预后因素。其他不良风险因素包括年龄>50岁(HR = 3.5)和肿瘤大小>4cm(HR = 2.5)。
在美国,AciCC在中年白人女性中更为常见,大多数肿瘤小于4cm且在诊断时为局限性病变。最相关的负面预后因素是高肿瘤分级,与死亡风险比相关的因素高于所有其他变量,包括就诊时的区域或远处转移。